124 related articles for article (PubMed ID: 37708846)
21. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
Sacchi A; Giannessi F; Sabatini A; Percario ZA; Affabris E
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298304
[TBL] [Abstract][Full Text] [Related]
22. Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics.
Cheemarla NR; Watkins TA; Mihaylova VT; Wang B; Zhao D; Wang G; Landry ML; Foxman EF
J Exp Med; 2021 Aug; 218(8):. PubMed ID: 34128960
[TBL] [Abstract][Full Text] [Related]
23. Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options.
Znaidia M; Demeret C; van der Werf S; Komarova AV
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746718
[TBL] [Abstract][Full Text] [Related]
24. Type I and III interferon responses in SARS-CoV-2 infection.
Kim YM; Shin EC
Exp Mol Med; 2021 May; 53(5):750-760. PubMed ID: 33953323
[TBL] [Abstract][Full Text] [Related]
25. CCR2 Signaling Restricts SARS-CoV-2 Infection.
Vanderheiden A; Thomas J; Soung AL; Davis-Gardner ME; Floyd K; Jin F; Cowan DA; Pellegrini K; Shi PY; Grakoui A; Klein RS; Bosinger SE; Kohlmeier JE; Menachery VD; Suthar MS
mBio; 2021 Dec; 12(6):e0274921. PubMed ID: 34749524
[TBL] [Abstract][Full Text] [Related]
26. Pre-infection antiviral innate immunity contributes to sex differences in SARS-CoV-2 infection.
Sauerwald N; Zhang Z; Ramos I; Nair VD; Soares-Schanoski A; Ge Y; Mao W; Alshammary H; Gonzalez-Reiche AS; van de Guchte A; Goforth CW; Lizewski RA; Lizewski SE; Amper MAS; Vasoya M; Seenarine N; Guevara K; Marjanovic N; Miller CM; Nudelman G; Schilling MA; Sealfon RSG; Termini MS; Vangeti S; Weir DL; Zaslavsky E; Chikina M; Wu YN; Van Bakel H; Letizia AG; Sealfon SC; Troyanskaya OG
Cell Syst; 2022 Nov; 13(11):924-931.e4. PubMed ID: 36323307
[TBL] [Abstract][Full Text] [Related]
27. Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN-
Anjum FR; Anam S; Abbas G; Mahmood MS; Rahman SU; Goraya MU; Abdullah RM; Luqman M; Ali A; Akram MK; Chaudhry TH
Viral Immunol; 2021 Jun; 34(5):321-329. PubMed ID: 33181057
[TBL] [Abstract][Full Text] [Related]
28. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.
Eskandarian Boroujeni M; Sekrecka A; Antonczyk A; Hassani S; Sekrecki M; Nowicka H; Lopacinska N; Olya A; Kluzek K; Wesoly J; Bluyssen HAR
Front Immunol; 2022; 13():888897. PubMed ID: 35663932
[TBL] [Abstract][Full Text] [Related]
29. Roles of Type I and III Interferons in COVID-19.
Choi H; Shin EC
Yonsei Med J; 2021 May; 62(5):381-390. PubMed ID: 33908208
[TBL] [Abstract][Full Text] [Related]
30. Virus Caused Imbalance of Type I IFN Responses and Inflammation in COVID-19.
Zhang J; Zhao C; Zhao W
Front Immunol; 2021; 12():633769. PubMed ID: 33912161
[TBL] [Abstract][Full Text] [Related]
31. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon.
Totura AL; Baric RS
Curr Opin Virol; 2012 Jun; 2(3):264-75. PubMed ID: 22572391
[TBL] [Abstract][Full Text] [Related]
32. [Interaction between SARS-CoV-2 and Host Innate Immunity].
Duan XQ; Xie H; Chen LM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Jan; 53(1):1-6. PubMed ID: 35048592
[TBL] [Abstract][Full Text] [Related]
33. Human Nasal and Lung Tissues Infected
Alfi O; Yakirevitch A; Wald O; Wandel O; Izhar U; Oiknine-Djian E; Nevo Y; Elgavish S; Dagan E; Madgar O; Feinmesser G; Pikarsky E; Bronstein M; Vorontsov O; Jonas W; Ives J; Walter J; Zakay-Rones Z; Oberbaum M; Panet A; Wolf DG
J Virol; 2021 Jun; 95(14):e0013021. PubMed ID: 33893170
[TBL] [Abstract][Full Text] [Related]
34. Effect of cannabidiol on apoptosis and cellular interferon and interferon-stimulated gene responses to the SARS-CoV-2 genes ORF8, ORF10 and M protein.
Fernandes MF; Chan JZ; Hung CCJ; Tomczewski MV; Duncan RE
Life Sci; 2022 Jul; 301():120624. PubMed ID: 35568225
[TBL] [Abstract][Full Text] [Related]
35. Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID-19).
Scagnolari C; Pierangeli A; Frasca F; Bitossi C; Viscido A; Oliveto G; Scordio M; Mazzuti L; Di Carlo D; Gentile M; Solimini A; Ceccarelli G; Pugliese F; Mastroianni CM; d'Ettorre G; Turriziani O; Antonelli G;
Virus Res; 2021 Apr; 295():198283. PubMed ID: 33418027
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways.
Han L; Zhuang MW; Deng J; Zheng Y; Zhang J; Nan ML; Zhang XJ; Gao C; Wang PH
J Med Virol; 2021 Sep; 93(9):5376-5389. PubMed ID: 33913550
[TBL] [Abstract][Full Text] [Related]
37. N7-Methylation of the Coronavirus RNA Cap Is Required for Maximal Virulence by Preventing Innate Immune Recognition.
Pan R; Kindler E; Cao L; Zhou Y; Zhang Z; Liu Q; Ebert N; Züst R; Sun Y; Gorbalenya AE; Perlman S; Thiel V; Chen Y; Guo D
mBio; 2022 Feb; 13(1):e0366221. PubMed ID: 35073761
[TBL] [Abstract][Full Text] [Related]
38. Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.
Metz-Zumaran C; Kee C; Doldan P; Guo C; Stanifer ML; Boulant S
J Virol; 2022 Apr; 96(7):e0170521. PubMed ID: 35262371
[TBL] [Abstract][Full Text] [Related]
39. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus.
Devaraj SG; Wang N; Chen Z; Chen Z; Tseng M; Barretto N; Lin R; Peters CJ; Tseng CT; Baker SC; Li K
J Biol Chem; 2007 Nov; 282(44):32208-21. PubMed ID: 17761676
[TBL] [Abstract][Full Text] [Related]
40. The main protease of SARS-CoV-2 cleaves histone deacetylases and DCP1A, attenuating the immune defense of the interferon-stimulated genes.
Song L; Wang D; Abbas G; Li M; Cui M; Wang J; Lin Z; Zhang XE
J Biol Chem; 2023 Mar; 299(3):102990. PubMed ID: 36758802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
